Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gastric Cancer
Oxaliplatin and SN-38 interacted synergistically in human gastric cancer cells
September 14th, 2005
Scientists claimed that oxaliplatin and SN-38 interacted synergistically in human gastric cancer cells. According to recent research published in the journal Oncology Reports, "The interaction between CPT-11 and oxaliplatin, a new platinum derivative that has a great antitumor activity against colon cancer, has not been determined in gastric cancer cells. In this study, we investigated in vitro cytotoxic activity of oxaliplatin alone or in combination with SN-38, an active metabolite of CPT-11, using different exposure schedules in three human gastric cancer cell lines (AZ-521, MKN-45, and NUGC-4)." "Cytotoxicity was determined by WST-1 assay....
Source: Vaccine Weekly (2005-09-14)
|
